Phuturdex › Diseases › Nervous System Diseases
Drugs in development · updated 30 October 2026
Nervous System Diseases: drugs in development
As of 30 October 2026 there are 42 active clinical trials (recruiting or ongoing, phases I–III) on 39 drugs for nervous System Diseases. 27 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| TSHA-102 | III | 2 | NCT07480564 |
| Ambroxol Hydrochloride | III | 1 | NCT05778617 |
| AOC 1044 | III | 1 | NCT07587242 |
| Cleminorexton | II–III | 1 | NCT07598708 |
| Deramiocel | III | 1 | NCT05126758 |
| Ecopipam | III | 1 | NCT06021522 |
| ECUR-506 | III | 1 | NCT06255782 |
| GNR-055 | II–III | 1 | NCT05208281 |
| NGN-401 | III | 1 | NCT05898620 |
| RiliprubartBIVV020 | III | 1 | NCT06290128 |
| ML-007C-MA | II | 3 | NCT07459647 |
| 4D-310 | I–II | 2 | NCT05629559 |
| VX-670 | I–II | 2 | NCT06185764 |
| AFA-281 | II | 1 | NCT06649747 |
| FBX-101 | I–II | 1 | NCT05739643 |
| FosigotifatorABBV-CLS-7262 | I–II | 1 | NCT05757141 |
| GS010 | II | 1 | NCT07303296 |
| GSK4527226 | II | 1 | NCT07105709 |
| Neflamapimod | II | 1 | NCT07033481 |
| Tianeptine | II | 1 | NCT06012552 |
| VIM0423 | II | 1 | NCT07804615 |
| AZD5492 | I | 1 | NCT06916806 |
| G207 | I | 1 | NCT03911388 |
| LY3954068 | I | 1 | NCT06297590 |
| NG004 | I | 1 | NCT06817577 |
| NIO752 | I | 1 | NCT05469360 |
| SNUG01 | Early I | 1 | NCT06645197 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| DonanemabKisunla® | III | 3 | NCT05508789 |
| DexamethasoneDexametasone, Dextenza | III | 1 | NCT05738486 |
| FinasteridePropecia®, Proscar® | II–III | 1 | NCT07742553 |
| RituximabRuxience, Rituxan | III | 1 | NCT05834855 |
| TenecteplaseTnkase®, Metalyse® | II–III | 1 | NCT05105633 |
| Testosterone cypionateAzmiro® | II–III | 1 | NCT07742553 |
| Testosterone EnanthateXyosted (Autoinjector)®, Delatestryl® | II | 1 | NCT04460872 |
| 18F-AV-1451[18F] Flortaucipir, Flortaucipir F18 | I | 1 | NCT06297590 |
| RiluzoleExservan®, Tiglutik Kit® | I | 1 | NCT07093268 |
| CenobamateXcopri®, Ontozry® | Early I | 1 | NCT06352723 |
| ModafinilProvigil® | Early I | 1 | NCT01988883 |
| PropranololHemangeol®, Innopran Xl® | Early I | 1 | NCT01988883 |
Sorted by most advanced phase and number of active trials.
All 39 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Brain Neoplasms 190 drugs
- Alzheimer's disease 157 drugs
- Ischemic stroke 94 drugs
- Parkinson's disease 104 drugs
- Multiple sclerosis 93 drugs
- Amyotrophic lateral sclerosis 79 drugs
- Stroke 70 drugs
- Glioma 184 drugs
- Myasthenia gravis 49 drugs
- Cognitive dysfunction 94 drugs
- Glioblastoma 245 drugs
- Duchenne muscular dystrophy 35 drugs
Broader categories
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities 4 drugs
- Nutritional and metabolic diseases 5 drugs
- Neurologic Manifestations 15 drugs
- Neurobehavioral manifestation 8 drugs
- Nervous system heredodegenerative disease 3 drugs
- Central nervous system disease 38 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: NLM MeSH; NLM MeSH term: D009422 “Nervous System Diseases”.